Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2008

l Besseghir, CEO of Debiopharm S.A. "This unique mechanism of action is the first alternative treatment to classic HCV therapies."

Debio 025

Debio 025 is a synthetic first-in-class Cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in preclinical studies.

Previous results of a phase Ib study demonstrate that Debio 025 monotherapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, Vol. 47, No 3, 2008, Flisiak et al. "The Cyclophilin Inhibitor Debio-025 Shows Potent Anti-Hepatitis C Effect in Patients Coinfected with Hepatitis C and Human Immunodeficiency Virus)."

About HCV

HCV is the most prevalent liver disease in the world and is considered by the World Health Organization as an epidemic. Because HCV can infect a patient for decades before being discovered, it is often called the "silent" epidemic. Studies suggest that over 200 million people worldwide are infected with HCV, an overall incidence of around 3.3% of the world's population. In the US alone, nearly 4 million people are or have been infected with HCV and of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old. A fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015, since most persons with chronic HCV infection have yet to be diagnosed but are likely to come to medical attention in the next decade.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marke
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
2. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
3. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
4. More Clinical Data Required to Support European Approval of CAP Indication for TYGACIL
5. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
8. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
9. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
10. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
11. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... WASHINGTON, Sept. 29, 2011 As small businesses struggle ... indicates concern that forthcoming Essential Health Benefits regulations ... drug companies to raise prescription drug costs, the ... benefit managers (PBMs) administer drug benefits for thousands of ...
... Atrium Medical Corporation today announced the publication ... Vascular Surgery.  COBEST ( Covered Versus Balloon Expandable ... multi center, randomized, controlled clinical trial that has ... technology is superior to traditional bare metal stents ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 Glutamine is ... and it’s considered to be conditionally essential during times ... is an advanced recovery & Immune System Support. , ... glutamine your body produces, supplementing with additional glutamine may ... waste products in the body, digestion and immune system ...
(Date:7/28/2014)... Maureen Salamon HealthDay Reporter ... Infants and children who are at risk of contracting ... against the infection, according to updated recommendations from the ... And routine vaccinations for the potentially deadly infection should ... of Pediatrics says. In its first statement on ...
(Date:7/28/2014)... Endurance runners are far more likely to die of ... a new study. The researchers pointed out ... are actually 10 times more likely to develop severe ... death of a young and apparently healthy person due ... often gets a lot more media attention. "This ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 ... recipe app for iOS, App is available on iTunes for ... first of its kind, Audio Chef allows you to listen ... gourmet cuisine the easy way: simply get out the ingredients ... no need to measure or prepare ingredients ahead of time, ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
Breaking Medicine News(10 mins):Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 2Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 3Health News:Audio Chef Co. Releases Audio Cooking App for iPhone/iPad/iPod touch 4Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... Harry Leider, M.D., MBA, FACPE, Ameritox,s Senior Vice President ... Chairman of the Board for the American College of Physician ... physician leaders. , , Dr. Leider became an ... faculty member within the College for 13 years teaching courses ...
... low cellular level of a tiny fragment of RNA ... mouse models of the disease, according to researchers at ... of this so-called microRNA, which is also associated with ... the likelihood of metastasis (which accounts for 90% of ...
... Morning Tuesday, June 16, 2009 at 9:00 a.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that ... equity of Symphony Allegro. The purchase of Symphony Allegro, ... close in Q3 2009. , , Alexza and Symphony ...
... AMDL Inc. (NYSE Alternext US: ADL), a US-based ... closing of a private placement offering of "units" consisting of 12% ... for the offering is Cantone Research Inc. , , In ... 12% Series 2 convertible notes at par value and completed the ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... Barak Obama speaks to the American Medical Association (AMA) today ... including physicians from coast to coast, is listening. ... will not support a public health insurance, option. Since the ... an anti-public insurance stance, the AMA is fostering the notion ...
Cached Medicine News:Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:RNA snippet suppresses spread of aggressive breast cancer 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:AMDL Inc. Announces Second Closing of Private Placement of Series 2 Senior Notes 2Health News:AMDL Inc. Announces Second Closing of Private Placement of Series 2 Senior Notes 3Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Indiana U. expert says nation's physicians support national health insurance 2
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
... wall .90 mm (20 g) ... 6 mm in length. Cannula ... sclerotomy. 3201 has 16 cm ... tubing to allow injection of ...
Medicine Products: